Skip to main content
OpenTrials
Completed

NCT Number: NCT03084965

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type II Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

Up to 99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Changhua, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Outpatient equal to or more than 20 years of age.
  • T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third line oral anti-diabetic therapy, either as add-on or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin.
  • Completed follow-up of at least 6 months regardless of continuation on dapagliflozin therapy.
  • Will provide completed and signed written informed consents.

Exclusion criteria

  • Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to Baseline.
  • Subjects with Type 1 diabetes.
  • Treatment with other investigational drugs concurrently during the retrospective data collection period.

Treatment and study plan

Primary outcomes

  1. Change in HbA1c

    Time frame: 6 months

    To assess the change from baseline (time to initiate dapagliflozin*) in HbA1c at 6 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Mar 21, 2017
Registry last updated
Feb 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.